Catalyst Biosciences, Inc. CBIO
We take great care to ensure that the data presented and summarized in this overview for CATALYST BIOSCIENCES, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CBIO
View allLatest Institutional Activity in CBIO
Top Purchases
Top Sells
About CBIO
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD. The company also develops ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms designed to target other disorders of the complement or inflammatory pathways. It has a strategic research collaboration with Mosaic Biosciences, Inc.; and license and collaboration agreement with Biogen International GmbH. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.
Insider Transactions at CBIO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 20
2024
|
Songjiang Ma President |
SELL
Open market or private sale
|
Indirect |
2,000
-0.07%
|
$20,000
$10.9 P/Share
|
|
Dec 19
2024
|
Songjiang Ma President |
SELL
Open market or private sale
|
Indirect |
2,000
-0.07%
|
$20,000
$10.82 P/Share
|
|
Dec 18
2024
|
Songjiang Ma President |
SELL
Open market or private sale
|
Indirect |
2,000
-0.03%
|
$22,000
$11.64 P/Share
|
|
Dec 17
2024
|
Songjiang Ma President |
SELL
Open market or private sale
|
Indirect |
2,000
-0.03%
|
$22,000
$11.09 P/Share
|
|
Jun 28
2024
|
Nassim Usman |
SELL
Open market or private sale
|
Direct |
3,452
-67.85%
|
$41,424
$12.0 P/Share
|
|
Jun 28
2024
|
Nassim Usman |
BUY
Exercise of conversion of derivative security
|
Direct |
3,452
+40.42%
|
$20,712
$6.93 P/Share
|
|
May 01
2024
|
Nassim Usman |
SELL
Open market or private sale
|
Direct |
20,000
-49.62%
|
$280,000
$14.8 P/Share
|
|
May 01
2024
|
Nassim Usman |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+48.04%
|
$120,000
$6.93 P/Share
|
|
Apr 01
2024
|
Nassim Usman |
SELL
Open market or private sale
|
Direct |
20,000
-92.44%
|
$320,000
$16.15 P/Share
|
|
Apr 01
2024
|
Nassim Usman |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+48.04%
|
$120,000
$6.93 P/Share
|
|
Mar 15
2024
|
Nassim Usman |
SELL
Open market or private sale
|
Direct |
20,000
-92.44%
|
$340,000
$17.26 P/Share
|
|
Mar 15
2024
|
Nassim Usman |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+48.04%
|
$120,000
$6.93 P/Share
|
|
Oct 30
2023
|
Ying Luo |
BUY
Other acquisition or disposition
|
Indirect |
2,840,376
+50.0%
|
-
|
|
Oct 30
2023
|
Gni Group Ltd. |
BUY
Other acquisition or disposition
|
Indirect |
63,588,119
+49.84%
|
-
|
|
Oct 27
2023
|
Gni Hong Kong LTD |
SELL
Other acquisition or disposition
|
Direct |
5,371,304
-100.0%
|
-
|
|
Aug 31
2023
|
Augustine Lawlor |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
24
-100.0%
|
-
|
|
Aug 31
2023
|
Augustine Lawlor |
SELL
Sale (or disposition) back to the issuer
|
Direct |
24
-100.0%
|
-
|
|
Aug 31
2023
|
Gni Group Ltd. |
SELL
Sale (or disposition) back to the issuer
|
Direct |
6,266
-100.0%
|
-
|
|
Aug 31
2023
|
Andrea Hunt |
SELL
Sale (or disposition) back to the issuer
|
Direct |
28
-100.0%
|
-
|
|
Aug 31
2023
|
Nassim Usman |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
9
-100.0%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 63.5K shares |
|---|
| Open market or private sale | 71.5K shares |
|---|